Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.
The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Company takeovers with promises of more cash down the road ticked up this year, a new Evaluate Vantage analysis finds.
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Device deal making is back in a big way, despite the munificence of venture funds.
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
And four other potential targets that could make sense for the beleaguered group.